» Articles » PMID: 34368069

The Relevance of Genomic Epidemiology for Control of Tuberculosis in West Africa

Overview
Specialty Public Health
Date 2021 Aug 9
PMID 34368069
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Tuberculosis (TB), an airborne infectious disease caused by complex (MTBC), remains a global health problem. West Africa has a unique epidemiology of TB that is characterized by medium- to high-prevalence. Moreover, the geographical restriction of to the sub-region makes West Africa have an extra burden to deal with a two-in-one pathogen. The region is also burdened with low case detection, late reporting, poor treatment adherence leading to development of drug resistance and relapse. Sporadic studies conducted within the subregion report higher burden of drug resistant TB (DRTB) than previously thought. The need for more sensitive and robust tools for routine surveillance as well as to understand the mechanisms of DRTB and transmission dynamics for the design of effective control tools, cannot be overemphasized. The advancement in molecular biology tools including traditional fingerprinting and next generation sequencing (NGS) technologies offer reliable tools for genomic epidemiology. Genomic epidemiology provides in-depth insight of the nature of pathogens, circulating strains and their spread as well as prompt detection of the emergence of new strains. It also offers the opportunity to monitor treatment and evaluate interventions. Furthermore, genomic epidemiology can be used to understand potential emergence and spread of drug resistant strains and resistance mechanisms allowing the design of simple but rapid tools. In this review, we will describe the local epidemiology of MTBC, highlight past and current investigations toward understanding their biology and spread as well as discuss the relevance of genomic epidemiology studies to TB control in West Africa.

Citing Articles

Opinion review of drug resistant tuberculosis in West Africa: tackling the challenges for effective control.

Otchere I, Asante-Poku A, Akpadja K, Diallo A, Sanou A, Asare P Front Public Health. 2024; 12():1374703.

PMID: 38827613 PMC: 11141065. DOI: 10.3389/fpubh.2024.1374703.


Hybrid use of Raman spectroscopy and artificial neural networks to discriminate Mycobacterium bovis BCG and other Mycobacteriales.

Macgregor-Fairlie M, De Gomes P, Weston D, Rickard J, Goldberg Oppenheimer P PLoS One. 2023; 18(12):e0293093.

PMID: 38079400 PMC: 10712843. DOI: 10.1371/journal.pone.0293093.


The Mycobacterium tuberculosis genome at 25 years: lessons and lingering questions.

Koleske B, Jacobs Jr W, Bishai W J Clin Invest. 2023; 133(19).

PMID: 37781921 PMC: 10541200. DOI: 10.1172/JCI173156.

References
1.
Zetola N, Moonan P, Click E, Oeltmann J, Basotli J, Wen X . Population-Based Geospatial and Molecular Epidemiologic Study of Tuberculosis Transmission Dynamics, Botswana, 2012-2016. Emerg Infect Dis. 2021; 27(3):835-844. PMC: 7920683. DOI: 10.3201/eid2703.203840. View

2.
Coscolla M, Gagneux S . Does M. tuberculosis genomic diversity explain disease diversity?. Drug Discov Today Dis Mech. 2010; 7(1):e43-e59. PMC: 2976975. DOI: 10.1016/j.ddmec.2010.09.004. View

3.
Unis G, Ribeiro A, Esteves L, Spies F, Picon P, Costa E . Tuberculosis recurrence in a high incidence setting for HIV and tuberculosis in Brazil. BMC Infect Dis. 2014; 14:548. PMC: 4215011. DOI: 10.1186/s12879-014-0548-6. View

4.
Baya B, Diarra B, Diabate S, Kone B, Goita D, Sarro Y . Association of Infection with Slower Disease Progression Compared with in Malian Patients with Tuberculosis. Am J Trop Med Hyg. 2019; 102(1):36-41. PMC: 6947796. DOI: 10.4269/ajtmh.19-0264. View

5.
Sobkowiak B, Glynn J, Houben R, Mallard K, Phelan J, Guerra-Assuncao J . Identifying mixed Mycobacterium tuberculosis infections from whole genome sequence data. BMC Genomics. 2018; 19(1):613. PMC: 6092779. DOI: 10.1186/s12864-018-4988-z. View